A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms HIJAK
- 06 Dec 2016 Results assessing efficacy and safety presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Sep 2016 Planned End Date changed from 1 May 2017 to 1 Jan 2018.
- 01 Sep 2015 Planned End Date changed from 1 Jun 2019 to 1 May 2017, as reported by ClinicalTrials.gov.